TENAX THERAPEUTICS INC (TENX) Stock News

USA - NASDAQ:TENX - US88032L6056 - Common Stock

7.5 USD

-0.18 (-2.41%)

Last: 11/19/2025, 2:57:12 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TENX Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Tenax Therapeutics, Inc.

Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Tenax Therapeutics, Inc.

Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF

3 months ago - By: Tenax Therapeutics, Inc.

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

3 months ago - By: The Motley Fool

Tenax Posts Wider Loss in Fiscal Q2

3 months ago - By: Tenax Therapeutics, Inc.

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

a year ago - By: BusinessInsider

News Image

TENX Stock Earnings: Tenax Therapeutics Beats EPS for Q2 2024

a year ago - By: InvestorPlace

TENX Stock Earnings: Tenax Therapeutics Beats EPS for Q2 2024

a year ago - By: InvestorPlace

Why Is Tenax Therapeutics (TENX) Stock Up 29% Today?

2 years ago - By: InvestorPlace

TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q1 2024

6 months ago - By: Tenax Therapeutics, Inc.

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

8 months ago - By: Tenax Therapeutics, Inc.

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

8 months ago - By: Tenax Therapeutics, Inc.

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

9 months ago - By: Tenax Therapeutics, Inc.

Tenax Therapeutics Announces $25 Million Private Placement

9 months ago - By: Tenax Therapeutics, Inc.

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

2 years ago - By: BusinessInsider

News Image

TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023

2 years ago - By: InvestorPlace

TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023

2 years ago - By: Benzinga

Tenax Therapeutics: Q4 Earnings Insights

2 years ago - By: Benzinga

Why Tenax Therapeutics (TENX) Stock Is Getting Obliterated

10 months ago - By: Tenax Therapeutics

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

a year ago - By: Tenax Therapeutics

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

a year ago - By: Tenax Therapeutics

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

a year ago - By: Tenax Therapeutics

Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

a year ago - By: Tenax Therapeutics

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

2 years ago - By: Tenax Therapeutics

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

2 years ago - By: InvestorPlace - Mentions: TIRX HOLO SECO SMFL ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

2 years ago - By: Tenax Therapeutics

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

2 years ago - By: Tenax Therapeutics

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

2 years ago - By: Tenax Therapeutics

Tenax Therapeutics to Present at the 36th Annual Roth Conference

2 years ago - By: Tenax Therapeutics

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

2 years ago - By: Tenax Therapeutics

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

2 years ago - By: InvestorPlace - Mentions: ACB DIS SAVE

ACB Stock Alert: The $50 Million Reason Aurora Cannabis Is Up Today